drugset
drugset / Trial / NCT00851773

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

NCT00851773 ↗

Phase 1 Completed 84 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this clinical trial is to assess and compare the safety and tolerability, as assessed by adverse events after multiple subcutaneous doses of NN9535 in healthy male Japanese and Caucasian subjects.

Timeline

Start
2009-02
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 0.1 mg Subcutaneous
Subject Semaglutide Peptide 0.2 mg Subcutaneous
Subject Semaglutide Peptide 0.4 mg Subcutaneous
Subject Semaglutide Peptide 0.8 mg Subcutaneous
Subject Semaglutide Peptide 1.2 mg Subcutaneous

Indications

diabetes mellitus